Trial Profile
A PHASE 1/2, OPEN-LABEL, ADAPTIVE, DOSE-RANGING STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF SB-525 (PF-07055480) (RECOMBINANT AAV2/6 HUMAN FACTOR 8 GENE THERAPY) IN ADULT SUBJECTS WITH SEVERE HEMOPHILIA A
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Giroctocogene fitelparvovec (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms Alta
- Sponsors Pfizer; Sangamo Therapeutics
- 12 Dec 2023 Updated results (data cutoff date: 19 May 2023) of 4 years of follow-up presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 02 Nov 2023 According to a Pfizer media release, data from this study will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 01 Nov 2023 According to a Sangamo BioSciences media release, company expect to present updated data with Pfizer from the Phase 1/2 ALTA study of giroctocogene fitelparvovec in an oral presentation at the 65th American Society for Hematology Annual Meeting and Exposition on December 11, 2023.